Sands Capital Management LLC Has $80.17 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Sands Capital Management LLC cut its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 7.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,485,724 shares of the biopharmaceutical company’s stock after selling 284,129 shares during the period. Sands Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $80,172,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assetmark Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the period. Danske Bank A S acquired a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $39,000. Smartleaf Asset Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $66,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Howard Horn sold 4,683 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $24.90, for a total value of $116,606.70. Following the completion of the transaction, the chief financial officer owned 110,342 shares of the company’s stock, valued at approximately $2,747,515.80. This trade represents a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Shehnaaz Suliman sold 5,740 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $25.12, for a total transaction of $144,188.80. Following the completion of the transaction, the director directly owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. This trade represents a 17.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,103 shares of company stock valued at $478,186. 5.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on RARE. Canaccord Genuity Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Guggenheim dropped their price objective on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, May 8th. JPMorgan Chase & Co. dropped their price objective on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. Finally, HC Wainwright dropped their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $59.56.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $24.35 on Monday. The company has a market cap of $2.40 billion, a P/E ratio of -3.99 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $42.37. The company has a fifty day simple moving average of $23.99 and a 200 day simple moving average of $25.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The business had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. During the same period last year, the business posted ($1.57) EPS. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.